Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Preoperative Evaluation of Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01455610

Enrollment

140

Registered

2011-10-20

Start date

2011-10-31

Completion date

2012-10-31

Last updated

2011-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of Head of Pancreas

Keywords

Computed tomography, Contrast enhancement, Pancreas, Cancer, Resectability

Brief summary

The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectability of pancreatic head cancer with contrasted-enhanced MDCT and its various post processing techniques, taking operational and pathological records as the gold standard.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with (or suspected) pancreatic head cancer * Being examined by contrasted-enhanced MDCT * Receiving surgical treatment (including palliative surgery) in all research centers

Exclusion criteria

* Patients having (or suspected) pregnancy or breast-feeding * Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs) * Patients receiving ERCP before contrasted-enhanced MDCT examination * Patients without surgery because of a high degree of surgical risk

Countries

China

Contacts

Primary ContactMengsu Zeng, MD, PhD

zengmengsu@gmail.com+86-021-64041990-2130

Backup ContactXiuzhong Yao, MD, PhD

fjqzyaoxz02@163.com+86-021-64041990-5425

Outcome results